So why is Roslin's Announcement Pivotal in the Execution of the European
Strategy and What is its major Implications relative to the US Strategy and
the Overall Value of ACTC?
Number One is it gives a very strong indication of a brilliant
Caldwell/Lanze growth strategy, product development vision that is
agressive, multi-faceted, and is not US Focused but is in fact Global.
Caldwell finally showed his brilliance by developing this strategy with
Lanza and Mickunas.
The Roslin Agreement will do the following for ACTC:
1. Initiate ACTC's European Strategy while continuing to work on its US
2. Implement the Gold Standard Blastomere Strategy in Europe independent
of US Political Stupidity and Governmental Burden.
3. It will give ACTC the Option to move to Europe in the Event that the US
Government makes it impossible to
Operate its core business in the US.
4. The European Strategy will make ACTC an A-Class and attractive
investment for many European Bio Pharmas.
5. The Roslin Agreement will allow the Blastomere Patent of ACTC to be the
Global Gold Standard by allowing its licensing to the World. Note that this
Global Strategy will allow ACTC's Blastomere Patent to dominate the
Regenerative Market because of the following: The critical quality of a
Blastomere Stemcell it is robustness and ability to differentiate into
almost all the cells in the human body. If you compare this to any Adult
Stem Cells you will note that Adult Stem Cells are in most cases NOT as
robust and as able to differentiate as a Blastomere Stem Cells.
Additionally, there are now studies that show early senecense for
non-blastomere type stem cells and mostly adult stem cells. More
importantly, ACTC/Roslin may in fact allow ACTC's Blastomer Stem Cells to be
as Universally Used as the "Microsoft Software" on a worldwide basis, and be
paid Royalties on all the products that will come out of this Agreement.
This Strategic Initiative is as important as the first US FDA Approval that
ACTC has received. Note that this Agreement will provide ACTC's Stem Cells
hundreds of labs, and thousands of scientists whose every success will
provide ACTC a stream of revenue and cash flow without having to manage each
of this labs. themselves. This is sheer genius if there ever is one. It was
applied at Microsoft and Google, but it is now being used in Regenerative
Medicine by ACTC.
6. The European Strategy and the Roslin Agreement will allow European
Funding and basically tell the NIH that they better move and make decisions
or Europe will leave you behind.
Other important implications of the European Strategy is simple, it makes
ACTC very attractive to Major BioPharmas as a JV Partner for Europe, the
same thing applies to the Japanese Pharma Companies. This will also
eliminate this talk about the need for an RS and possibly early takeover by
a Major Pharma Company.
The Roslin Agreement all of a sudden makes ACTC a Global Stem Cell Company,
albiet still small, but a very attractive JV Partner at a very good price
That's a post from a manager at Google Groups. He's a valuable member of the google group because he always provides inteligent posts such as that one. That's just 1 of hundreds he has put out. Visit the google board, become a member and enjoy smart conversations.
I would if I had that info....my buddy sent it to me from a private ACTC board. I don't think the guy is looking for publishing credits....just wanted to pass it along to other investors as I'm sure he would like....what good is it giving credit to a screen name anyways....it's just a good read from a good post.